A randomised phase III trial comparing two dose-dense, dose-intensified approaches (ETC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)

Authors :: Klare, P
Ingold-Heppner, B
Blohmer, J-U
Hanusch, C
Jackisch, C
Kast, K
Tesch, H
Huober, J
Loibl, S
Denkert, C
Kümmel, S
Thomalla, J
Rezai, M
Untch, M
Lübbe, K
von Minckwitz, G
Möbus, V
Schneeweiss, A
Nekljudova, V
Publication Year :: 2017

Tools